rabeprazole has been researched along with Diarrhea in 3 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Excerpt | Relevance | Reference |
---|---|---|
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 9.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
"The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD)." | 5.19 | Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. ( Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014) |
"Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 5.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
"Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Haddad, I | 2 |
Kierkus, J | 2 |
Tron, E | 2 |
Ulmer, A | 2 |
Hu, P | 2 |
Sloan, S | 2 |
Silber, S | 2 |
Leitz, G | 1 |
Leitz, GJ | 1 |
Wong, BC | 1 |
Wong, WM | 1 |
Yee, YK | 1 |
Hung, WK | 1 |
Yip, AW | 1 |
Szeto, ML | 1 |
Li, KF | 1 |
Lau, P | 1 |
Fung, FM | 1 |
Tong, TS | 1 |
Lai, KC | 1 |
Hu, WH | 1 |
Yuen, MF | 1 |
Hui, CK | 1 |
Lam, SK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891] | Phase 3 | 127 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36
Intervention | Scores on a scale (Mean) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | 0.2 |
Rabeprazole Sodium 1.0 mg/kg | 0.2 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12
Intervention | Scores on a scale (Mean) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | -1.3 |
Rabeprazole Sodium 1.0 mg/kg | -1.0 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36
Intervention | Scores on a scale (Mean) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | -2.9 |
Rabeprazole Sodium 1.0 mg/kg | -1.4 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12
Intervention | Scores on a scale (Mean) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | -11.5 |
Rabeprazole Sodium 1.0 mg/kg | -8.5 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks
Intervention | Percentage of participants (Number) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | 78 |
Rabeprazole Sodium 1.0 mg/kg | 83 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks
Intervention | Percentage of patients (Number) |
---|---|
Rabeprazole Sodium 0.5 mg/kg | 92 |
Rabeprazole Sodium 1.0 mg/kg | 88 |
3 trials available for rabeprazole and Diarrhea
Article | Year |
---|---|
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es | 2013 |
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
Topics: Abdominal Pain; Child; Child, Preschool; Diarrhea; Double-Blind Method; Endoscopy, Gastrointestinal; | 2014 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |